TELEFLEX INCORPORATED (NYSE:TFX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On December 10, 2018, the Board of Directors (the “Board”) of Teleflex Incorporated (the “Company”) elected John C. Heinmiller to the Board, effective January 1, 2019. The Board also designated Mr. Heinmiller to serve on the Audit Committee of the Board, effective upon commencement of his service as a director. Mr. Heinmiller was elected to fill the vacancy created as a result of W. Kim Foster’s retirement from the Board earlier this year and will stand for re-election at the Company’s 2019 annual meeting of stockholders.
Mr. Heinmiller, 64, retired in January 2017 after a 19-year career with St. Jude Medical, Inc. (“St. Jude Medical”), a global medical device company. During his tenure with St. Jude Medical, Mr. Heinmiller served in various executive and senior level positions, includingExecutive Vice President from August 2012 to January 2017; Executive Vice President and Chief Financial Officer from May 2004 to August 2012; Vice President, Finance and Chief Financial Officer from September 1998 to May 2004; and Vice President of Corporate Business Development from May 1998 to September 1998. Prior to joining St. Jude Medical, Mr. Heinmiller held senior management positions with and was a member of the board of directors of Daig Corporation, a medical device company, and LifeCore Biomedical, a medical technology company.
In connection with his service on the Board, Mr. Heinmiller will receive compensation consistent with the compensation currently provided to all Company non-employee directors, as described on pages 15 and16 of the Company’s proxy statement for its 2018 annual meeting of stockholders, filed with the Securities and Exchange Commission on March 30, 2018.
Mr. Heinmiller was identified as a potential Board candidate by one of the Company’s external advisers. There are no arrangements or understandings between Mr. Heinmiller, on the one hand, and the Company or any other persons, on the other hand, to which Mr. Heinmiller was selected as a director. There are no related party transactions between the Company and Mr. Heinmiller (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K.
About TELEFLEX INCORPORATED (NYSE:TFX)
Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company markets and sells its products to hospitals and healthcare providers, across the world, through a combination of its direct sales force and distributors. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM). The Company manufactures its products at approximately 30 manufacturing sites, with manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. The Company’s all others businesses include single-use respiratory, urology and cardiac care products, as well as capital equipment.
